RNAi News GenomeWeb News Premium Content Existing subscribers login here. New to RNAi News? For a trial subscription click here.

Investment Firm Accelerator Launches miRNA
Drug Developer, Licenses Nanogen MGB Tech

[August 21, 2008]

By Doug Macron

The company, called Mirina, will develop microRNA antagonists that have been modified with minor groove binders, which are expected to boost the oligos’ target selectivity and potency. The agreement with Nanogen marks the first time the company has licensed its MGB assets for therapeutic applications.

Login | Subscribe